Sequential Therapy with PARP and WEE1 Inhibitors Minimizes Toxicity while Maintaining Efficacy
Yong Fang(The University of Texas MD Anderson Cancer Center), Daniel J. McGrail(The University of Texas MD Anderson Cancer Center), Chaoyang Sun(The University of Texas MD Anderson Cancer Center), Marilyne Labrie(The University of Texas MD Anderson Cancer Center), Xiaohua Chen(The University of Texas MD Anderson Cancer Center), Dong Zhang(The University of Texas MD Anderson Cancer Center), Zhenlin Ju(The University of Texas MD Anderson Cancer Center), Christopher P. Vellano(The University of Texas MD Anderson Cancer Center), Yiling Lu(The University of Texas MD Anderson Cancer Center), Yongsheng Li(The University of Texas MD Anderson Cancer Center), Kang Jin Jeong(The University of Texas MD Anderson Cancer Center), Zhiyong Ding(The University of Texas MD Anderson Cancer Center), Jiyong Liang(The University of Texas MD Anderson Cancer Center), Steven W. Wang(The University of Texas MD Anderson Cancer Center), Hui Dai(The University of Texas MD Anderson Cancer Center), Sanghoon Lee(The University of Texas MD Anderson Cancer Center), Nidhi Sahni(The University of Texas MD Anderson Cancer Center), Imelda Mercado‐Uribe(The University of Texas MD Anderson Cancer Center), Tae-Beom Kim(The University of Texas MD Anderson Cancer Center), Ken Chen(The University of Texas MD Anderson Cancer Center), Shiaw‐Yih Lin(The University of Texas MD Anderson Cancer Center), Guang Peng(The University of Texas MD Anderson Cancer Center), Shannon N. Westin(The University of Texas MD Anderson Cancer Center), Jinsong Liu(The University of Texas MD Anderson Cancer Center), Mark J. O’Connor(AstraZeneca (United Kingdom)), Timothy A. Yap(The University of Texas MD Anderson Cancer Center), Gordon B. Mills(The University of Texas MD Anderson Cancer Center)
Cited by 239Open Access
Abstract
Related Papers
No related papers found
Powered by citation graph analysis